We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL) (CURTAXEL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02095717
Recruitment Status : Terminated (The trial was stopped for futility in view of the results of the interim analysis)
First Posted : March 26, 2014
Last Update Posted : July 24, 2018
Sponsor:
Information provided by (Responsible Party):
Centre Jean Perrin

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Multicenter randomized phase II study, double-blind, comparing Taxotere plus curcumin versus Taxotere plus placebo combination in first-line treatment of prostate cancer metastatic castration resistant. Assess time to progression (time to progression) of metastatic disease (from first day of treatment in the trial).

Condition or disease Intervention/treatment Phase
Prostate Cancer Metastatic Castration Resistant Drug: Curcumin Drug: Placebo Drug: Taxotere Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Study Start Date : March 2014
Actual Primary Completion Date : April 2018
Actual Study Completion Date : April 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Curcumin

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Curcumin
curcumine capsule
 Drug: Curcumin
Drug: Taxotere
Placebo Comparator: Placebo
placebo capsule
 Drug: Placebo
Drug: Taxotere


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Time to progression [ Time Frame: participants will be followed post treatment. From date of randomization until the date of first documented progression or date of death from any cause ]

    Assess time to progression (time to progression) of metastatic disease (from first day of treatment in the trial). Progression was defined as an increase (of) injury (s) tumor (s) (RECIST) or an increase in PSA levels (≥ 25% and ≥ 2ng/ml increase) or the appearance of new lesions metastatic (at least 2 new lesions for bone lesions).

    From date of randomization until the date of first documented progression or date of death from any cause



Secondary Outcome Measures :
  1. PSA response [ Time Frame: From date of randomization until the date of first documented PSA progression or date of death from any cause ]
    Evaluate the PSA response (50% decrease compared to the initial value)

  2. objective tumor response rate [ Time Frame: participants will be evaluated at the end of the treatment (randomization + an expected average of 4 months) ]
    Evaluate the objective tumor response rate (CR + PR) by RECIST.

  3. safety and tolerability [ Time Frame: patients will be followed for the duration of the treatment, an expected average of 4 months ]
    Assess the safety (adverse events) of the combination Taxotere/ curcumin.

  4. Pain [ Time Frame: participants will be followed at Cycle1,3,6 of chemotherapy and post treatment (+1months after the end of the treatment) ]
    Assess pain in the short questionnaire on pain (QCD)

  5. neuroendocrine markers [ Time Frame: participants will be followed for the duration of the treatment, an expected average of 4 months ]
    Assess serum neuroendocrine markers

  6. Overall survival [ Time Frame: from date of randomization until the date of death from any cause ]
    Evaluate overall survival (between inclusion and death whatever the cause)

  7. anti-angiogenic activity [ Time Frame: participants will be followed at each Cycle of chemotherapy ( + inclusion) , an expected average of 4 months ]
    Evaluate the anti-angiogenic activity of the association Taxotere ® plus curcumin

  8. compliance [ Time Frame: patients will be followed for the duration of the treatment, an expected average of 4 months ]
    Assess the compliance by curcumin treatment / placebo orally


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient older than 18 years.
  • Performance status ≤ 2 according to the WHO criteria.
  • Life expectancy> 3 months.
  • Patient in hormonal blockade based on surgical castration by orchiectomy or pulpectomy, medical or agonist or antagonists of LHRH associated or not with anti-androgens or any other treatment that blocks the fraction of non-gonadal testosterone, resulting in a testosterone <0.5 ng / mL.
  • Patient with adenocarcinoma of the prostate and histologically proven metastatic castration-resistant stage, defined by: objective progression of at least one measurable tumor target and / or assessable by RECIST, and / or increase in PSA ("rising PSA").
  • Satisfactory biological functions (renal, hepatic and hematologic)
  • Patient who signed the consent for participation before entering the study.
  • Affiliation to a social security scheme (or be the beneficiary of such a plan) under the terms of the law of 9 August 2004.

Exclusion Criteria:

  • Age <18 years.
  • Performance status> 2 according to the WHO criteria.
  • Patient deprived of liberty or under guardianship, patient with (the) condition (s) psychological, family, social or geographic may interfere with the proper conduct of the study.
  • Diagnosis of a second malignancy in the past 5 years, with the exception of a basal cell skin cancer considered cured.
  • Patient with brain metastases at initial assessment.
  • Patient with another pathology deemed incompatible with the inclusion in the protocol.
  • Laboratory tests inadequate.
  • History of malabsorption syndrome or extensive resection of the upper digestive tract.
  • Uncontrolled intercurrent infection.
  • Pathology autoimmune and / or chronic active inflammation.
  • peripheral neuropathy grade 2 according to the criteria of the National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE, version 4.0).
  • History of allergy to polysorbate 80.
  • Treatment with nonsteroidal anti-inflammatory and / or cyclooxygenase-2 dated within three weeks.
  • Concomitant with a drug test or participation in another clinical trial within <30 days treatment.
  • Regular Taking dietary supplements.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02095717


Locations
Layout table for location information
France
Clinique de la Chataigneraie
Beaumont, France
Centre Jean Perrin
Clermont-Ferrand, France
Centre Hospitalier Emile Roux
Le Puy en velay, France
Institut Jean Godinot
Reims, France
Sponsors and Collaborators
Centre Jean Perrin
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Centre Jean Perrin
ClinicalTrials.gov Identifier: NCT02095717    
Other Study ID Numbers: 2013-002138-20
First Posted: March 26, 2014    Key Record Dates
Last Update Posted: July 24, 2018
Last Verified: July 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases
Curcumin
Docetaxel
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
 Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Enzyme Inhibitors